| SHP | Schonlein-Henoch purpura; secondary hyperparathyroidism; state health plan |
|---|---|
| sHPT | secondary hyperparathyroidism |
| SIMS | secondary ion mass spectroscopy |
| SL | sarcolemma; sclerosing leukoencephalopathy; secondary leukemia; segment length; sensation level; sen... |
| SMDS | secondary myelodysplastic syndrome |
| pregnancy, multiple | The condition of bearing two or more foetuses simultaneously. (12 Dec 1998) |
|---|---|
| pregnancy outcome | Results of conception and ensuing pregnancy, including live birth, stillbirth, spontaneous abortion, induced abortion. The outcome may follow natural or artificial insemination or any of the various reproduction techniques, such as embryo transfer or fertilization in vitro. (12 Dec 1998) |
| pregnancy planning | Pregnancy planning addresses issues of nutrition, vitamins, body weight, exercise, and potentially harmful medications and illnesses as well as immunizations and genetic counseling. (12 Dec 1998) |
| pregnancy, prolonged | Pregnancy continuing beyond the normal duration; in humans, usually beyond 294 days after the beginning of the last menses. (12 Dec 1998) |
| pregnancy proteins | Proteins produced by organs of the mother or the placenta during pregnancy. They may be either pregnancy specific (present only during pregnancy) or pregnancy associated (always present during pregnancy, but may also be present in individuals undergoing oestrogen therapy, taking oral contraceptives or in patients with certain malignancies.) (12 Dec 1998) |
| pregnancy rate | Ratio of the number of conceptions that occur during a period to the mean number of women of reproductive age. (12 Dec 1998) |
| pregnancy reduction, multifetal | Selective abortion of one or more embryos or foetuses in a multiple gestation pregnancy. The usual goal is to improve the outcome for the remaining embryos or foetuses. (12 Dec 1998) |
| pregnancy-specific beta 1-glycoprotein | A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test. (12 Dec 1998) |
| pregnancy tests | Tests to determine whether or not an individual is pregnant. (12 Dec 1998) |
| pregnancy toxaemia of sheep | A disease of preparturient ewes characterised primarily by impaired nervous function; the primary predisposing cause is undernutrition in late pregnancy. Synonym: ovine acetonaemia. (05 Mar 2000) |
| pregnancy toxaemias | Pregnancy-induced hypertensive states, including eph gestosis when oedema and proteinuria accompany hypertension. Other hypertensive disorders that develop during pregnancy or the puerperium are preeclampsia and eclampsia, either of which may be superimposed upon chronic hypertensive vascular or renal disease. (12 Dec 1998) |
| pregnancy trimester, first | Period of pregnancy from the first day of the last normal menstrual period through the completion of 14 weeks (98 days) of gestation. (12 Dec 1998) |
| pregnancy trimesters | The three periods of three months each in the normal pregnancy. (12 Dec 1998) |
| pregnancy trimester, second | Period of pregnancy from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. (12 Dec 1998) |
| pregnancy trimester, third | Period of pregnancy from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. (12 Dec 1998) |